Avaliação do potencial terapêutico do tiabendazol para tratamento da esquistossomose mansoni experimental
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidade Federal de Juiz de Fora (UFJF)
Abstract
Schistosomiasis is a neglected tropical disease, endemic in several countries, and
generates serious socioeconomic consequences. The causative trematode belongs to
the genus Schistosoma spp. The lack of a vaccine reinforces the role of chemotherapy
in controlling morbidity and disease transmission. The most used drug is praziquantel,
yet it does not have a pediatric dosage form. Its bitter taste and the size of the tablet
contribute to keeping the treatment from being adhered to by children. Furthermore,
praziquantel does not prevent reinfection. Consequently, another treatment option is
necessary, thus, the effectiveness of the drug thiabendazole in the suspension form
was evaluated, since it is intended for pediatric use. To verify the thiabendazole
effectiveness, Swiss mice, preferably females, were infected with 80 ± 10
cercariae/animal. A total of 136 animals were divided into groups for different
treatments, such as an uninfected and untreated group; a control group composed of
infected and untreated animals; a positive control group with infected animals treated
with a dose of praziquantel (400mg/Kg). The other groups of animals received oral
doses of thiabendazole 50mg/kg and thiabendazole 100mg/kg after 30 days of
infection, this period was intended for evaluating the effect of the treatment on young
worms. Other groups received the same oral doses of thiabendazole 50mg/kg and
thiabendazole 100mg/kg, however, the treatment was after 45 days of infection to
evaluate the effect of the treatment on adult worms. The schistosomicidal action was
analyzed after 7 days of treatment, through the euthanasia of the animals. The
proposed thiabendazole treatment in both concentrations did not reduce the parasite
load and did not interfere with oviposition. The liver and splenic weight analysis
indicated an increase in these masses with the course of the infection when compared
to the group G2. The study on the granuloma area revealed that the groups treated
with TBZ had a smaller area. The production of antibodies was analyzed against the
SEA and SWAP antigens and the groups G4 and G5 did not show significant reactivity
when compared to group G2. Finally, the hepatotoxicity assay showed that TBZ in the
used doses of 50 and 100 mg/kg did not show toxicity.In conclusion, the repositioning
of the drug thiabendazole in the two-dose therapeutic scheme used at concentrations
of 50 mg/kg and 100 mg/kg is not classified as a good therapeutic option in the fight
against schistosomiasis mansoni. Given the data obtained, it is necessary to carry out
new tests with this drug.
Description
Keywords
Citation
Endorsement
Review
Supplemented By
Referenced By
Creative Commons license
Except where otherwise noted, this item's license is described as Acesso Aberto

